Vice President of Manufacturing, Compass Therapeutics
Ph.D., Biology, State University of New York, Binghamton
B.S., Biochemistry, State University of New York, Binghamton
Area(s) of Expertise
Process development and manufacturing for biotherapeutics, downstream development, formulation development and analytical sciences, regulatory
Dr. Gregory Zarbis-Papastoitsis is Vice President of Process Development and Manufacturing Sciences at Eleven Biotherapeutics. His group develops and transfers clinical and commercial enabling processes to CMO facilities, and manages all activities regarding the development and manufacturing of Bulk Drug Substance and Drug Product. Prior to Eleven he was the Senior Director of the Downstream Development and Analytical groups at PERCIVIA, LLC, where they developed platform technologies for recombinant molecules produced with the PER.C6® human cell line. Before he was Associate Director of Process Development and Analytical Sciences at Syntonix Pharmaceuticals in Waltham, MA. While at Syntonix, he was responsible for the early clinical development of a long lasting Factor IX, which was approved in US and Canada in March 2014 (Aprolix™, Biogen Idec). Prior to Syntonix, Dr. Zarbis-Papastoitsis spent several years with organizations such as Repligen, Seragen (worked on the purification development of IL2-Diptheria Toxin (ONTAK®)), Millennium Pharmaceuticals, and Abbott Biologics. At Abbott he was one of the key scientists that designed the second-generation commercial manufacturing process for HUMIRA®.